Exelixis, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared

SG&A Spending Patterns: Exelixis, Inc. vs. Perrigo Company plc

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and Perrigo Company plc from 2014 to 2023. Over this period, Exelixis, Inc. has seen a remarkable increase in SG&A spending, growing by over 900%, from approximately $51 million in 2014 to $543 million in 2023. This surge reflects the company's aggressive expansion and marketing strategies. In contrast, Perrigo Company plc, a more established entity, has maintained a steady SG&A expenditure, with a modest 89% increase, reaching $1.27 billion in 2023. This stability underscores Perrigo's focus on maintaining operational efficiency while navigating market challenges. These spending patterns offer a window into the strategic priorities of these companies, highlighting their distinct approaches to growth and market presence.